Biodexa Pharmaceuticals receives Fast Track designation for eRapa
Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...
Nasdaq4d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
The designation was requested based on the potential for eRapa to address an unmet medical need for FAP, a condition which left untreated universally leads to colorectal cancer. Today, the only ...
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous PolyposisUnderscores unmet need for a ...
Nasdaq4d
FDA Grants Fast Track Designation To Biodexa's ERapa For Familial Adenomatous Polyposis
(RTTNews) - Biodexa Pharmaceuticals PLC (BDRX), a clinical-stage biopharmaceutical company, announced on Monday that its lead drug candidate, eRapa, has been granted Fast Track Designation by the ...
Yahoo Finance4d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of ...
Yahoo Finance4d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with ...
manilatimes4d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
The designation was requested based on the potential for eRapa to address an unmet medical need for FAP, a condition which left untreated universally leads to colorectal cancer. Today, the only ...